Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement
2001; Wiley; Volume: 41; Issue: 4 Linguagem: Inglês
10.1046/j.1537-2995.2001.41040560.x
ISSN1537-2995
AutoresAndreas Laupacis, Janice Brown, Brenda Costello, Gilles Delage, John Freedman, Heather Hume, Susan King, Steve Kleinman, Tony Mazzulli, George Wells,
Tópico(s)Pneumocystis jirovecii pneumonia detection and treatment
ResumoTransfusionVolume 41, Issue 4 p. 560-569 Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement Andreas Laupacis, Andreas Laupacis From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorJanice Brown, Janice Brown From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorBrenda Costello, Brenda Costello From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorGilles Delage, Gilles Delage From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorJohn Freedman, John Freedman From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorHeather Hume, Heather Hume From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorSusan King, Susan King From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorSteve Kleinman, Steve Kleinman From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorTony Mazzulli, Tony Mazzulli From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorGeorge Wells, George Wells From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this author Andreas Laupacis, Andreas Laupacis From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorJanice Brown, Janice Brown From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorBrenda Costello, Brenda Costello From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorGilles Delage, Gilles Delage From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorJohn Freedman, John Freedman From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorHeather Hume, Heather Hume From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorSusan King, Susan King From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorSteve Kleinman, Steve Kleinman From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorTony Mazzulli, Tony Mazzulli From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this authorGeorge Wells, George Wells From the Institute for Clinical Evaluative Sciences; St. Michael's Hospital; The Hospital for Sick Children; and the Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada: the Division of Bone Marrow Transplantation, Stanford University Medical Center, Palo Alto, California; the Public Health Laboratory of Quebec, Sainte-Anne-de-Bellevue, Quebec, Canada; the Hematology Department, Ste-Justine Hospital, Montreal, Quebec, Canada; and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.Search for more papers by this author First published: 21 April 2002 https://doi.org/10.1046/j.1537-2995.2001.41040560.xCitations: 65 Address correspondence to: Andreas Laupacis, MD, MSc, FRCPC, Institute for Clinical Evaluative Sciences, G106, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5; e-mail: [email protected]. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Available at: http://odp.od.nih.gov/consensus/about/about.htm. Google Scholar 2 Blajchman MA, Goldman M, Freedman JJ, Sher GD. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev 2001; 15: 1 – 20. 10.1053/tmrv.2001.19946 CASPubMedWeb of Science®Google Scholar 3 Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after bone marrow transplantation. J Infect Dis 1986; 153: 478 – 88. 10.1093/infdis/153.3.478 PubMedGoogle Scholar 4 Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 1993; 55: 1339 – 46. 10.1097/00007890-199306000-00024 CASPubMedWeb of Science®Google Scholar 5 Griffiths PD, Baboonian C. A prospective study of primary cytomegalovirus infection during pregnancy: final report. Br J Obstet Gynaecol 1984; 91: 307 – 15. 10.1111/j.1471-0528.1984.tb05915.x PubMedWeb of Science®Google Scholar 6 Stagno S. Cytomegalovirus. In: J Remington, G Klein, eds. Infectious diseases of the fetus and newborn. Philadelphia: WB Saunders, 1995: 312 – 53. Google Scholar 7 Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12(Suppl 7): S754 – 66. 10.1093/clinids/12.Supplement_7.S754 PubMedWeb of Science®Google Scholar 8 Preiksaitis JK, Brown L, McKenzie M. Transfusion-acquired cytomegalovirus infection in neonates. A prospective study. Transfusion 1988; 28: 205 – 9. 10.1046/j.1537-2995.1988.28388219143.x CASPubMedWeb of Science®Google Scholar 9 Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006 – 10. 10.1056/NEJM198604173141602 PubMedWeb of Science®Google Scholar 10 Miller WJ, McCullough J, Bafour HH Jr, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7: 227 – 34. CASPubMedWeb of Science®Google Scholar 11 Preiksaitis JK, Rosno S, Grumet C, et al. Infections due to herpes virus in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. J Infect Dis 1983; 147: 974 – 81. 10.1093/infdis/147.6.974 PubMedWeb of Science®Google Scholar 12 Preiksaitis JK, Desai S, Vaudry W, et al. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study. Transfusion 1997; 37: 941 – 6. 10.1046/j.1537-2995.1997.37997454022.x PubMedWeb of Science®Google Scholar 13 Luthardt T, Siebert H, Losel I, et al. [Cytomegalovirus infections in infants with blood exchange transfusions after birth] (Engl abstract). Klin Wochenschr 1971; 49: 81 – 6. 10.1007/BF01497304 PubMedWeb of Science®Google Scholar 14 Kumar A, Nankervis GA, Cooper AR, et al. Acquisition of cytomegalovirus infection in infants following exchange transfusion: a prospective study. Transfusion 1980; 20: 327 – 31. 10.1046/j.1537-2995.1980.20380214901.x CASPubMedWeb of Science®Google Scholar 15 Yeagar AS, Grumet FC, Hafleigh EB, et al. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981; 98: 281 – 7. 10.1016/S0022-3476(81)80662-2 PubMedWeb of Science®Google Scholar 16 MacKinnon S, Burnett AK, Crawford RJ, et al. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol 1988; 41: 948 – 50. 10.1136/jcp.41.9.948 CASPubMedWeb of Science®Google Scholar 17 Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598 – 603. CASPubMedWeb of Science®Google Scholar 18 Gilbert GL, Hayes K, Hudson IL, et al. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes. Lancet 1989; 2: 1228 – 31. 10.1016/S0140-6736(89)92330-1 PubMedWeb of Science®Google Scholar 19 Murphy MF, Grint PC, Hardiman AE, et al. Use of leukocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukemia (letter). Br J Haematol 1988; 70: 253 – 4. 10.1111/j.1365-2141.1988.tb02473.x PubMedWeb of Science®Google Scholar 20 De Graan-Hentzen YC, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematological malignancies by intensive white cell depletion of blood products. Transfusion 1989; 29: 757 – 60. 10.1046/j.1537-2995.1989.29990070177.x PubMedWeb of Science®Google Scholar 21 Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246 – 50. PubMedWeb of Science®Google Scholar 22 Brady MT, Milam JD, Anderson DC, et al. Use of deglycerolized red blood cells to prevent posttransfusion infection with cytomegalovirus in neonates. J Infect Dis 1984; 150: 334 – 9. 10.1093/infdis/150.3.334 PubMedWeb of Science®Google Scholar 23 Eisenfeld L, Silver H, Mclaughlin J, et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 1992; 32: 205 – 9. 10.1046/j.1537-2995.1992.32392213801.x PubMedWeb of Science®Google Scholar 24 Tolkoff-Rubin NA, Rubin RH, Keller EE, et al. Cytomegalovirus infection in dialysis patients and personnel. Ann Intern Med 1978; 89: 625 – 8. 10.7326/0003-4819-89-5-625 CASPubMedWeb of Science®Google Scholar 25 Betts RF, Cestero RV, Freeman RB, Douglas RG. Epidemiology of CMV infection in end stage renal disease. J Med Virol 1979; 4: 89 – 96. 10.1002/jmv.1890040203 CASPubMedWeb of Science®Google Scholar 26 De Witte T, Schattenberg A, Van Dijk BA, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood bank donors. Transplantation 1990; 50: 964 – 8. 10.1097/00007890-199012000-00013 PubMedWeb of Science®Google Scholar 27 Van Prooijen HC, Visser JJ, Van Oostendorp WR, et al. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 1994; 87: 144 – 7. 10.1111/j.1365-2141.1994.tb04884.x PubMedWeb of Science®Google Scholar 28 Pamphilon DH, Rider JR, Barbara JA, Williamson LM. Prevention of transfusion-transmitted cytomegalovirus infection. Transfus Med 1999; 9: 115 – 23. 10.1046/j.1365-3148.1999.00193.x CASPubMedWeb of Science®Google Scholar 29 Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion 1999; 39: 665 – 70. 10.1046/j.1537-2995.1999.39070665.x CASPubMedWeb of Science®Google Scholar Citing Literature Volume41, Issue4April 2001Pages 560-569 ReferencesRelatedInformation
Referência(s)